Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy.

Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy. Pediatr Res. 2017 Oct 10;: Authors: Nabetani M, Shintaku H, Hamazaki T Abstract Neonatal ischemic brain injury causes permanent motor-deficit cerebral palsy. Hypoxic-ischemic encephalopathy (HIE) is a very serious condition that can result in death and disability. In 1997, we reported that irreversible neuronal cell damage is induced by the elevation of intracellular Ca ion concentration that has occurred in sequence after excess accumulation of the excitatory neurotransmitter glutamate during ischemia. We also reported that hypothermia was effective in treating ischemic brain damage in rats by suppressing energy loss and raising intracellular Ca ion concentration. Following the 2010 revised International Liaison Committee on Resuscitation guideline, our group developed the Guideline for the treatment of Hypothermia in Japan, and we started online case registry in January 2012. However, therapeutic hypothermia must be initiated within the first 6 h after birth. By contrast, cell therapy may have a much longer therapeutic time window because it might reduce apoptosis/oxidative stress and enhance the regenerative process. In 2014, we administered autologous umbilical cord blood stem cell (UCBC) therapy for neonatal HIE, for the first time in Japan. We enrolled five full-term newborns with moderate to severe HIE. Our autologous UCBC therapy is leading to...
Source: Pediatric Research - Category: Pediatrics Authors: Tags: Pediatr Res Source Type: research